Sound Income Strategies LLC Acquires 387,027 Shares of Perrigo Company plc $PRGO

Sound Income Strategies LLC lifted its holdings in Perrigo Company plc (NYSE:PRGO) by 34.0% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 1,525,384 shares of the company’s stock after purchasing an additional 387,027 shares during the period. Sound Income Strategies LLC’s holdings in Perrigo were worth $16,779,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Janney Montgomery Scott LLC raised its stake in Perrigo by 9.6% in the first quarter. Janney Montgomery Scott LLC now owns 35,053 shares of the company’s stock worth $376,000 after buying an additional 3,073 shares in the last quarter. Louisiana State Employees Retirement System purchased a new position in shares of Perrigo in the 1st quarter valued at $655,000. Corient Private Wealth LLC purchased a new position in shares of Perrigo in the 4th quarter valued at $283,000. Alpine Global Management LLC bought a new position in shares of Perrigo in the 4th quarter worth $181,000. Finally, Aristides Capital LLC bought a new position in shares of Perrigo in the 4th quarter worth $212,000. 95.91% of the stock is currently owned by institutional investors.

Perrigo Stock Performance

Shares of PRGO stock opened at $11.01 on Friday. The business’s fifty day simple moving average is $10.90 and its 200-day simple moving average is $12.13. The company has a market cap of $1.52 billion, a PE ratio of -0.84, a PEG ratio of 1.22 and a beta of 0.51. The company has a current ratio of 2.72, a quick ratio of 1.59 and a debt-to-equity ratio of 1.45. Perrigo Company plc has a 12-month low of $9.23 and a 12-month high of $28.43.

Perrigo (NYSE:PRGO) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.39 by $0.04. The firm had revenue of $841.80 million during the quarter, compared to analyst estimates of $1.04 billion. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The business’s revenue for the quarter was down 7.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.60 EPS. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Analysts expect that Perrigo Company plc will post 2.11 earnings per share for the current fiscal year.

Perrigo Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 16th. Shareholders of record on Friday, May 29th were paid a $0.29 dividend. The ex-dividend date was Friday, May 29th. This represents a $1.16 dividend on an annualized basis and a yield of 10.5%. Perrigo’s dividend payout ratio (DPR) is -8.85%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on PRGO. Zacks Research raised Perrigo from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Weiss Ratings upgraded shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 15th. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $19.33.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.